Drug
Aralast Alpha1 Proteinase Inhibitor
Aralast Alpha1 Proteinase Inhibitor: highest development phase Post-Market, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARALAST Alpha1-Proteinase Inhibitor NCT00313144 | Post-Market | Alpha1-antitrypsin Deficiency |
Latest
No recent events.
Follow Aralast Alpha1 Proteinase Inhibitor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.